close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY:BSX)

94.95 -0.46 (-0.48%)
Official Closing Price Updated: 7:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Boston Scientific

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
20 21 Next >
Boston Scientific Surges On Its 'Impressive' First-Quarter Guidance
The company expects sales to grow 7% to 9% organically, above expectations. 
Via Investor's Business Daily
Stryker, Boston Scientific Score Earnings Beats, Extend Breakouts
Shares of Stryker, Boston Scientific jumped early Wednesday after healthy earnings beats and price target hikes from analysts. 
Via Investor's Business Daily
Topics Earnings
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook. 
Via Benzinga
Topics Economy
Boston Scientific Corporation Should Continue Uptrend & Remain Supported
Boston Scientific Corporation develops, manufactures & markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg & Cardiovascular segments. 
Via Talk Markets
Looking Into Boston Scientific's Recent Short Interest
 
Via Benzinga
Demystifying Boston Scientific: Insights From 10 Analyst Reviews
 
Via Benzinga
Why Axonics Stock Soared Today
The medical device maker agreed to be acquired by Boston Scientific. 
Via The Motley Fool
Earnings Scheduled For January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
Preview: Boston Scientific's Earnings
 
Via Benzinga
Health Care Company Boston Scientific Announces Acquisition of Axonics
 
Via Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years
 
Via Benzinga
Boston Scientific Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
 
Via Benzinga
NYSE:BSX may be ready to breakout.
BOSTON SCIENTIFIC CORP (NYSE:BSX) Reveals Intriguing Technical Aspects. Here's What You Need to Know. 
Via Chartmill
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth. 
Via Benzinga
Chart Of The Day: Boston Scientific - Revenue Growth Potential
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. 
Via Talk Markets
Palo Alto Networks, Nvidia, And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed slightly lower on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
7 Healthcare Stocks Taking Medicine to the Next Level
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
Via InvestorPlace
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
5 A-Rated Stocks to Buy ASAP in 2024
2024 is ushering in a new era for investors, and these top-notch, A-rated stocks to buy are likely to be market winners. Here's why. 
Via InvestorPlace
10 Top Stocks With a Strong Buy Rating Right Now
Wall Street is highly bullish on these strong buy stocks, even as financial markets face an uncertain year. Here are the names to watch. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Is Axonics (AXNX) Stock Up 20% Today?
Axonics stock is rising higher on Monday as investors react to a $71 per share cash offer for AXNX stock from Boston Scientific. 
Via InvestorPlace
Why Is Bladder Disorder Focused Axonics Stock Trading Higher Today?
Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $7 
Via Benzinga
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
The year's biggest medical conference kicked off with a melee of buyout news. 
Via Investor's Business Daily
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
From Axonics, Inc.
Via Business Wire
Stock Picks 2024: 7 Trailblazers Using AI to Revolutionize Their Industries
Although AI-related stock picks for 2024 may be centered on tech firms, the innovation itself achieves broad relevance. 
Via InvestorPlace
Topics Artificial Intelligence
Why Medical Devices Behemoth Boston Scientific Shares Are Rising Friday
Boston Scientific Corporation (NYSE: BSX) said it expects FARAPULSE Pulsed Field Ablation (PFA) System to get  
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today